Drug intelligence / Profile preview

KNA-200

Development stage: Unknown
Lead developer: Kinea Bio
Modality: Gene Therapies

Overview

KNA-200 is an investigational gene therapy developed by Kinea Bio Inc. It is currently in the discovery phase and is being explored for the treatment of cardiomyopathies, a group of diseases that affect the heart muscle. The specific mechanism of action, molecular target(s), and detailed modality characteristics have not been publicly disclosed as of June 2025. Its development is focused within the therapeutic area of cardiovascular diseases[1][2][6].

Beyond the preview

Go deeper on KNA-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNA-200.

Explore the full profile